Does Resveratrol Actually Work? What the Trials Show

Resveratrol is the compound that launched the modern longevity supplement industry. Two decades on, the human trial data is in — and it is considerably more sobering than the marketing. This guide applies the evidence hierarchy from our longevity supplements guide to resveratrol supplements, and the conclusion is less flattering than most pages selling the ingredient.

Welzo sells it — Ultra Purity Trans-Resveratrol — alongside the wider anti-ageing and longevity supplements category and the NMN range it is often paired with: NMN benefits, side effects and dosage, NMN supplements and NMN Pro 1000. Read what follows knowing that.

The reputation came with a compelling origin story, a Nobel-adjacent scientific hypothesis, a $720 million pharmaceutical acquisition and endless coverage about red wine holding the secret to a long life. If you want a single sentence: resveratrol's reputation was built on mouse studies and an elegant mechanism, and the human evidence has largely failed to follow.

This article goes through where the story came from, what the trials actually found, why bioavailability is the likely explanation, and who — if anyone — might still reasonably take it.

Where the resveratrol story came from

The French paradox

The starting point was an epidemiological puzzle: the observation that France had relatively low rates of coronary heart disease despite a diet high in saturated fat, attributed to regular red wine consumption and specifically to the polyphenols in it [1]. Resveratrol became the leading candidate.

The problem with that inference was visible from the start. Red wine contains more than three dozen polyphenols, and wine drinking clusters with a whole dietary and social pattern. Picking one molecule out of that and declaring it the active agent was a hypothesis, not a finding.

The sirtuin hypothesis and the $720 million bet

The mechanism that made resveratrol famous was sirtuin activation — specifically SIRT1, an enzyme linked to the effects of calorie restriction on lifespan in model organisms. If a molecule in wine activated the same pathway as calorie restriction, the implications were obvious and enormous.

In 2008, GlaxoSmithKline acquired Sirtris Pharmaceuticals, the company built on this hypothesis, for $720 million. Its lead candidate was SRT501, a proprietary formulation of resveratrol [5,6].

The mechanism itself became contested

What is less widely reported is that the underlying science was disputed within the field. A significant line of research argued that resveratrol's apparent activation of SIRT1 in laboratory assays was partly an artefact of the assay design — specifically, of the fluorescent tag used on the test substrate rather than a property of the enzyme reaction itself. Under assay conditions using native substrates, the direct activation effect was substantially harder to demonstrate.

The debate was never fully resolved in public, and defenders of the hypothesis argued for indirect mechanisms instead. But the practical significance is this: the headline mechanism that justified a $720 million acquisition and a decade of consumer marketing was, at the time it was being sold to the public, actively contested among the scientists closest to it.

How that ended

In 2010, GSK suspended a phase 2a trial of SRT501 in advanced multiple myeloma after five patients developed acute renal failure, and subsequently halted development of the compound entirely. The company's stated analysis was that the renal failures were most likely attributable to the underlying disease — cast nephropathy is a common complication of myeloma — though it acknowledged the formulation was poorly tolerated, with nausea, vomiting and diarrhoea potentially causing dehydration that exacerbated the problem. Crucially, GSK also concluded that the formulation "may only offer minimal efficacy", and moved its resources to synthetic sirtuin activators instead [5,6,7].

What the human trials actually show

In healthy people: the Chianti study

This is the study that should feature in every resveratrol article and appears in almost none of them.

Researchers followed 783 community-dwelling adults aged 65 and over in the Chianti region of Italy — a population with high habitual red wine intake — from 1998 to 2009, measuring urinary resveratrol metabolites as an objective marker of dietary exposure. Over roughly nine years of follow-up, total urinary resveratrol metabolite concentration was not associated with inflammatory markers, cardiovascular disease or cancer, and did not predict all-cause mortality. The authors concluded that resveratrol levels achieved through a Western diet did not substantially influence health status or mortality risk in this population [1].

The lead author's own summary was blunt: the story of resveratrol turned out to be another case where a lot of hype about health benefits did not stand the test of time [1].

Two fair caveats. This measured dietary resveratrol, not supplement doses, which are far higher. And it is observational, so it demonstrates association rather than causation. But it is the largest, longest, most objective test of the core "resveratrol makes you live longer" claim that exists in humans, and it came back negative.

In type 2 diabetes: the one area with a signal

Where resveratrol does show something, it is in metabolic disease rather than healthy ageing.

A systematic review and meta-analysis of 15 randomised controlled trials involving 896 patients with type 2 diabetes found that resveratrol reduced HOMA-IR, a measure of insulin resistance, compared with control (weighted mean difference −0.99; 95% CI −1.61 to −0.38; p = 0.002). Total cholesterol and triglycerides showed no statistically significant difference, and there was no significant difference in adverse events between groups [2].

A separate meta-analysis examining resveratrol in type 2 diabetics on hypoglycaemic therapy assessed renal function and blood pressure markers across five RCTs and 388 participants, and described the evidence on cardiovascular-related profiles in this group as conflicting [3].

Blood pressure

A meta-analysis of randomised controlled trials found that overall, resveratrol consumption did not significantly reduce systolic or diastolic blood pressure. Subgroup analysis found that higher doses (≥150 mg/day) significantly reduced systolic blood pressure by approximately 11.9 mmHg (95% CI −20.99 to −2.81), while lower doses showed no significant effect and no significant effect was seen on diastolic pressure [8].

An 11.9 mmHg systolic reduction would be clinically meaningful if it held up. The wide confidence interval and the absence of an overall effect mean it should be treated as a hypothesis for further testing rather than an established benefit.

The evidence at a glance

The exercise interference finding

This one deserves its own section because it is the most practically important and the least discussed.

A double-blind, randomised, placebo-controlled study published in The Journal of Physiology assigned 27 healthy but physically inactive men aged around 65 to eight weeks of high-intensity exercise training three times weekly, alongside either 250 mg/day resveratrol or placebo.

Exercise training improved cardiovascular health parameters, as expected. But the resveratrol group showed blunted improvements: lower interstitial prostacyclin, higher muscle thromboxane synthase, and abolished positive effects of exercise on LDL cholesterol, total cholesterol/HDL ratio and triglycerides compared with placebo. The authors concluded that concomitant resveratrol supplementation can blunt the positive effects of exercise training in aged men [4].

The proposed mechanism, and the pushback

The suggested explanation is that exercise generates reactive oxygen species which act as necessary signalling molecules driving adaptation. A potent antioxidant taken alongside training may suppress that signal — the same argument previously made about high-dose vitamin C and E supplementation blunting training adaptations.

In fairness, this finding was contested. Published editorial responses argued the conclusions were too strong for a study of 27 men, and other trials have not consistently replicated it [4]. It is one trial, not a settled fact.

But it is a good illustration of why "antioxidant" is not automatically a synonym for "beneficial", and why the burden of proof should sit with the product rather than the buyer. If you train seriously, this is worth knowing about — see zone 2 training for longevity and supplements for endurance athletes.

The bioavailability problem

There is a plausible explanation for why a molecule with such striking laboratory effects does so little in people, and it is unglamorous: very little of it reaches your tissues in an active form.

Resveratrol is absorbed reasonably well but then extensively metabolised in the gut wall and liver into sulphate and glucuronide conjugates. Free resveratrol concentrations in plasma are consequently very low and short-lived — orders of magnitude below the concentrations that produce effects in cell culture experiments.

This matters enormously for how you read the preclinical literature. A study showing dramatic effects on cells in a dish at a given concentration tells you very little if that concentration is unachievable in living humans at any tolerable oral dose. Much of the resveratrol excitement rests on exactly that kind of extrapolation.

What resveratrol teaches you about every other longevity compound

This is the most useful thing to take from the resveratrol story, because the pattern repeats constantly across the category:

• A striking mechanism is not a result. Sirtuin activation was elegant, plausible and heavily funded. It did not translate.
• Cell-culture concentrations are frequently unachievable in humans. Always ask whether the dose that worked in a dish is reachable in a body.
• Mouse healthspan findings translate poorly. This is the rule, not the exception.
• Commercial validation is not scientific validation. A $720 million acquisition told you what a pharmaceutical company hoped, not what the evidence showed.
• Watch what the well-resourced players stop doing. When a company with every incentive to succeed walks away citing minimal efficacy, that is informative [5,6].

Apply those five tests to any longevity compound you are considering and you will avoid most of the category's expensive mistakes. We use the same framework in longevity supplements that don't work and is NMN a scam?

Trans vs cis, dosing and delivery claims

Trans-resveratrol is the form to look for

Resveratrol exists as two isomers. Trans-resveratrol is the biologically relevant, more stable form and the one used in essentially all clinical research. Cis-resveratrol is not. Any product worth considering will specify trans-resveratrol, usually extracted from Japanese knotweed rather than grapes, because the yield is far higher.

Dosing

Trials have used a wide range. The exercise study used 250 mg/day [4]; the blood pressure subgroup effect appeared at ≥150 mg/day [8]; metabolic trials in type 2 diabetes have used from under 250 mg up to 1,000 mg and above [2,9]. A dose-stratified meta-analysis in type 2 diabetes found glucose reductions at various dose bands with results varying by participant age [9], which is another way of saying the dose-response relationship is not clean.

There is no established optimal dose for healthy adults, because there is no established benefit in healthy adults to optimise for.

Liposomal and enhanced-delivery claims

Given the bioavailability problem, enhanced delivery formats are a logical idea, and they command a premium accordingly. The honest position is that improving a blood level is not the same as improving an outcome, and no enhanced-delivery resveratrol product has demonstrated better clinical results in humans. See the liposomal resveratrol collection and our comparison of resveratrol vs pterostilbene, a related compound with better bioavailability on paper.

Who might reasonably still take it

Having been fairly negative, here is the honest case for the defence:

• People with type 2 diabetes or metabolic syndrome, where the signal on insulin resistance is real if modest, and where meta-analysis found no significant difference in adverse events versus control [2]. This should be a conversation with your doctor, not a self-prescription, particularly if you take hypoglycaemic medication.
• People running a broad longevity protocol who understand the uncertainty. Resveratrol is inexpensive relative to newer compounds, has a reasonable tolerability record at supplement doses, and the possibility of benefit is not zero. Taking it as a low-conviction bet with money you can afford to waste is a defensible personal decision.
• People who have already covered everything better evidenced. If your vitamin D, omega-3, magnesium, creatine, sleep, training and diet are genuinely handled, adding a speculative compound costs you little. Most people asking about resveratrol have not done this — see our minimal supplement stack and cheap longevity stack.

Who should avoid it

• Anyone taking anticoagulants or antiplatelet medication. Resveratrol has antiplatelet activity and may increase bleeding risk. Speak to your GP or pharmacist first.
• Anyone on medication metabolised by cytochrome P450 enzymes, which resveratrol can inhibit — this covers a large number of common drugs. This is a pharmacist conversation.
• Anyone with a hormone-sensitive condition. Resveratrol has phytoestrogenic activity, and the implications for oestrogen-sensitive conditions are not well characterised. Seek medical advice.
• Anyone pregnant or breastfeeding. Not suitable.
• Anyone in a serious training block may wish to consider the exercise interference finding [4] before combining it with a hard programme.
• Anyone on a limited budget. This should be nowhere near your first purchase.

How to buy it if you decide to

Welzo's option is Ultra Purity Trans-Resveratrol at £24.99, with the full range in the resveratrol collection. It is also available paired in the NMN & Resveratrol stack at £41.99 and the NMN + Trans-Resveratrol + PQQ bundle at £59.99. Further reading: third-party tested supplements, how to read a certificate of analysis and the NMN, TMG and resveratrol stack.

Our position, stated plainly

We sell resveratrol. Here is what we actually think:

• The healthy-ageing case is weak. The largest long-term human study of dietary resveratrol found no association with mortality, cardiovascular disease, cancer or inflammation [1].
• The metabolic case is modest but real. In type 2 diabetes specifically, meta-analysis shows a reduction in insulin resistance [2].
• The mechanism story outran the evidence. A $720 million pharmaceutical bet on this molecule was written off partly for minimal efficacy [5,6].
• It should be low on your list. Below vitamin D, omega-3, magnesium, creatine, sleep and training. Possibly below NMN, which at least reliably moves the biomarker it claims to — see is NMN a scam?
• If you take it, take it as a low-conviction bet. Not as a cornerstone, and not on the strength of anything you have read about mice.

Related reading: longevity supplements that don't work, NAD supplement guide, spermidine vs NMN, fisetin vs quercetin, berberine vs metformin, the hallmarks of ageing, Blue Zones longevity, how long supplements take to work and longevity stack cost in the UK.

When to speak to a doctor

Speak to your GP or pharmacist before taking resveratrol if you take any prescription medication — particularly anticoagulants, antiplatelet drugs, or anything metabolised by cytochrome P450 enzymes — or if you have a hormone-sensitive condition, liver or kidney disease, or are pregnant, breastfeeding or trying to conceive.

If you are considering resveratrol because of concerns about blood pressure, cholesterol or blood sugar, those warrant proper measurement and clinical management rather than a supplement. A cholesterol blood test, HbA1c blood test or Full Body MOT Health Check will tell you far more than any supplement will do for you, and treatments with strong evidence exist for all three.

Frequently asked questions

Does resveratrol actually work?

For healthy ageing and longevity, the human evidence does not support it. A prospective study of 783 older adults found urinary resveratrol metabolite levels were not associated with inflammatory markers, cardiovascular disease, cancer or all-cause mortality [1]. There is a modest signal on insulin resistance in people with type 2 diabetes [2], and an inconsistent one on systolic blood pressure at higher doses [8]. It is a much weaker case than the marketing implies.

Why is resveratrol so famous if the evidence is weak?

Because the origin story was excellent. It combined the "French paradox" of red wine and heart health with the sirtuin hypothesis linking it to calorie restriction and lifespan, and was validated commercially when GlaxoSmithKline acquired Sirtris Pharmaceuticals for $720 million in 2008 [5,6]. Striking mouse results followed. The human data arrived later and much more quietly.

Did GSK really abandon resveratrol?

Yes. GSK suspended its phase 2a trial of the resveratrol formulation SRT501 in advanced multiple myeloma in 2010 after five patients developed acute renal failure, and later halted development entirely, stating the formulation may offer only minimal efficacy while potentially exacerbating a renal complication common in that patient group [5,6,7]. GSK's own analysis attributed the renal failures most likely to the underlying myeloma rather than to resveratrol.

Is resveratrol dangerous?

At typical supplement doses in healthy people, it has a reasonable tolerability record, and meta-analysis in type 2 diabetes found no significant difference in adverse events versus control [2]. The kidney failures in the GSK trial occurred in seriously ill myeloma patients taking 5 grams daily. The genuine concerns for ordinary users are drug interactions — anticoagulants, antiplatelet drugs and medicines metabolised by cytochrome P450 enzymes.

Should I take resveratrol with NMN?

The pairing is common and has a mechanistic rationale, since sirtuins are NAD⁺-dependent. There is no human trial demonstrating that the combination produces better outcomes than either alone. If you want to take both, that is a reasonable personal choice, but it should be framed as a hypothesis rather than an evidence-based protocol. See the NMN, TMG and resveratrol stack.

Can I just drink red wine instead?

No — and this is where the origin story falls apart entirely. The resveratrol content of wine is very low; you would need an implausible and dangerous quantity to approach supplement doses. More importantly, the Chianti study measured a population of habitual wine drinkers and found no benefit associated with resveratrol exposure [1]. Alcohol carries its own well-documented risks that are not offset by polyphenol content.

Does resveratrol interfere with exercise?

One randomised, double-blind, placebo-controlled trial in 27 aged men found that 250 mg/day resveratrol alongside eight weeks of high-intensity training blunted training-induced improvements in blood pressure, LDL cholesterol, cholesterol ratio and triglycerides compared with placebo [4]. The finding was contested in published responses as an overinterpretation of a small study, and has not consistently replicated. If you train seriously, it is worth being aware of.

What dose of resveratrol should I take?

There is no established dose for healthy adults, because there is no established benefit in healthy adults. Trials have used from under 150 mg to over 1,000 mg per day, with a blood pressure signal appearing at ≥150 mg in subgroup analysis [8] and metabolic trials spanning a wide range [2,9]. If you take it, trans-resveratrol in the 150–500 mg range covers most of the studied territory.

Is trans-resveratrol better than regular resveratrol?

Yes, in the sense that trans-resveratrol is the biologically active and more stable isomer, and is what has been used in clinical research. Any product not specifying trans-resveratrol should be treated with suspicion. Most is extracted from Japanese knotweed, which makes it suitable for plant-based diets — see our vegan longevity supplements guide.

What should I take instead?

If your goal is healthy ageing and your budget is finite, the boring options have vastly stronger evidence: vitamin D, omega-3, magnesium and creatine, plus sleep, resistance training and cardiovascular fitness. Our minimal supplement stack and cheap longevity stack set out what that looks like in practice.

References

1. Semba RD, Ferrucci L, Bartali B, et al. Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Internal Medicine. 2014;174(7):1077–1084. https://pubmed.ncbi.nlm.nih.gov/24819981/ — summary from the National Institute on Aging: https://www.nia.nih.gov/news/resveratrol-does-not-affect-health-longevity-population-study
2. Zhang T, He Q, Liu Y, Chen Z, Hu H. Efficacy and Safety of Resveratrol Supplements on Blood Lipid and Blood Glucose Control in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evidence-Based Complementary and Alternative Medicine. 2021;2021:5644171. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410426/
3. Nyambuya TM, Nkambule BB, Mazibuko-Mbeje SE, et al. A Meta-Analysis of the Impact of Resveratrol Supplementation on Markers of Renal Function and Blood Pressure in Type 2 Diabetic Patients on Hypoglycemic Therapy. Molecules. 2020;25(23):5645. https://pmc.ncbi.nlm.nih.gov/articles/PMC7730696/
4. Gliemann L, Schmidt JF, Olesen J, et al. Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men. The Journal of Physiology. 2013;591(20):5047–5059. https://physoc.onlinelibrary.wiley.com/doi/abs/10.1113/jphysiol.2013.258061
5. Fierce Biotech. Weak efficacy, renal risks force GSK to dump a resveratrol program. 2010. https://www.fiercebiotech.com/biotech/weak-efficacy-renal-risks-force-gsk-to-dump-a-resveratrol-program
6. Lowe D. Resveratrol (SRT501): Development Halted. Science (AAAS), In the Pipeline. 2010. https://www.science.org/content/blog-post/resveratrol-srt501-development-halted
7. Popat R, Plesner T, Davies F, et al. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. British Journal of Haematology. 2013;160(5):714–717. https://onlinelibrary.wiley.com/doi/10.1111/bjh.12154
8. Effect of resveratrol on blood pressure: A meta-analysis of randomized controlled trials. Clinical Nutrition. 2015;34(1):27–34. https://www.clinicalnutritionjournal.com/article/S0261-5614(14)00084-3/abstract
9. Influence of Age and Dose on the Effect of Resveratrol for Glycemic Control in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. Molecules. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9416262/
10. NHS. Vitamin D — Vitamins and minerals. https://www.nhs.uk/conditions/vitamins-and-minerals/vitamin-d/
11. Kreider RB, Kalman DS, Antonio J, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal of the International Society of Sports Nutrition. 2017;14:18. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469049/
12. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the Tolerable Upper Intake Level of EPA, DHA and DPA. EFSA Journal. 2012;10(7):2815. https://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2012.2815

All product photography in this article is owned by Welzo and served from the Welzo media library. Prices correct at the time of publication and subject to change.